GT Biopharma, Inc.
GTBP evidence brief
What we can confirm
- BioSniper Score:
- 3.4 / 10
- Market Cap:
- $15.5M
- Lead Asset:
- gtb-3650 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for GTBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GTBP
GT Biopharma, Inc. (GTBP) is a clinical-stage immuno-oncology company developing TriKE® and Dual Targeting TriKE® fusion protein platforms to treat hematologic malignancies, solid tumors, and autoimmune disorders.
Key risk: Cash runway limited
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$15.5M
Cash Runway
—
Lead Asset
gtb-3650 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 35 clinical trials for GT Biopharma, Inc..
GT Biopharma, Inc. (GTBP) is a clinical-stage immuno-oncology company developing TriKE® and Dual Targeting TriKE® fusion protein platforms to treat hematologic malignancies, solid tumors, and autoimmune disorders.
- Cash & equivalents of $5.0M as of 2026-06-30 [sec].
- Net income of -$4.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $3.6M as of 2026-06-30 [sec].
- FDA clearance of a new IND for GTB-5550 in multiple myeloma under an IST protocol [news · published 2026-09-15].
- Phase 1 basket trial for GTB-5550 in solid tumors actively enrolling, with an update anticipated in Q4 2026 [news · published 2026-09-15].
What works
- Three TriKE® candidates have entered the clinic, demonstrating platform scalability and clinical progress [news · published 2026-05-14].
- The company has secured FDA IND clearance for GTB-5550 in multiple myeloma, expanding its potential addressable market [news · published 2026-09-15].
- Integration of AI-based tools across discovery and engineering may enhance pipeline efficiency [news · published 2026-08-14].
What to weigh
- The company reported a net loss of $4.5M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- Phase 1 trial initiation for GTB-5550 in multiple myeloma is contingent upon receipt of non-dilutive grant funding, creating uncertainty [news · published 2026-09-15].
- Cash balance of approximately $11M as of September 15, 2026, may provide limited runway given operating losses [news · published 2026-09-15].
From the filings
Quoted directly from source documents.
FDA clearance for GTB-5550 in multiple myeloma
“FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol”
News · September 15, 2026
Phase 1 basket trial update expected in Q4 2026
“Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026”
News · September 15, 2026
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash of $5.0M as of 2026-06-30 and $11M as of 2026-09-15 may be insufficient given net losses of $4.5M per period [sec] [news].
- Trial initiation contingent on grant — Phase 1 trial for GTB-5550 in multiple myeloma depends on receipt of non-dilutive grant funding, creating execution risk [news].
- No approved products — All candidates are in Phase 1; no revenue from product sales, relying on external funding [sec_mda].
What to watch
- Phase 1 basket trial update for GTB-5550 in solid tumors expected in Q4 2026 [news · published 2026-09-15].
- Phase 1 trial update for GTB-3650 in relapsed/refractory AML anticipated in 2H 2026 [news · published 2026-08-14].
- Receipt of non-dilutive grant funding to initiate GTB-5550 multiple myeloma trial [news · published 2026-09-15].
- Cash runway and ability to fund operations given net losses [sec].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run GT Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GT Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$5M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 1.7%
- Days to cover
- 1.0
- Shares short
- 604,557
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GTBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for GT Biopharma, Inc.?
GT Biopharma, Inc. (GTBP) is a clinical-stage immuno-oncology company developing TriKE® and Dual Targeting TriKE® fusion protein platforms to treat hematologic malignancies, solid tumors, and autoimmune disorders.
What is GT Biopharma, Inc.'s lead drug candidate?
GT Biopharma, Inc.'s most advanced tracked candidate is gtb-3650 (Phase 1) for Relapsed/refractory AML and high-risk MDS.
Who is the CEO of GT Biopharma, Inc.?
Mr. Michael Martin Breen L.L.B. is the chief executive officer of GT Biopharma, Inc. (GTBP).
Where is GT Biopharma, Inc. headquartered?
GT Biopharma, Inc. (GTBP) is headquartered in San Francisco, CA, United States.
What therapeutic areas does GT Biopharma, Inc. focus on?
GT Biopharma, Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Infectious Disease, Metabolic, Pain, Dermatology, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.